BlueBay and HSBC provide debt for £83m Synexus buyout

© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

BlueBay and HSBC provide debt for £83m Synexus buyout

drugs

BlueBay and HSBC have provided debt to support a secondary buyout of Synexus, the UK clinical trials coordinator, by LDC, the private equity arm of Lloyds Bank.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login
  • 4,000 annual insights
  • 700+ notes and long-form analyses
  • 4 capital markets databases
  • Daily newsletters across markets and asset classes
  • 2 weekly podcasts
Gift this article